Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06995443
Recruiting Not applicable

Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment

NCT06995443 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier de Valenciennes
Phase
Not applicable
Started
2025-06-13
Last updated
2026-01-30

Condition(s) studied

OncologySupport CareCognitive Disorders

Investigational drug(s) / intervention(s)

Photobiomodulation

Photobiomodulation: 12 sessions of photobiomodulation (1 per week) Visit 1 to 4 : photobiomodulation (NOVOTHOR) + cortical stimulation (VEILIGHT) Visit 5 to 12 : cortical stimulation (VEILIGHT)

Study summary

Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50. Treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapies and hormone therapy. Although chemotherapy is not systematically used, it remains a frequent treatment option. While chemotherapy makes a major contribution to curing cancer, it is also a source of potentially disabling side effects for survivors.

Chemotherapy can interfere with the normal functioning of the central nervous system, leading to cognitive impairment. The number of people potentially affected by chemobrain is estimated at several tens of millions worldwide. There is no recommended treatment for people with chemobrain. Several avenues have been explored, with very limited results. Photobiomodulation (PBM) is a non-medicinal treatment technique that combines all the biological, athermic and non-cytotoxic effects of tissue exposure to non-ionizing sources of red and infrared light. Several studies have demonstrated the beneficial effects of cortical stimulation by photobiomodulation on memory (increased angiogenesis, increased oxygenation of brain tissue via vasodilatation, and increased mitochondrial ATP production). These positive biological effects are likely to ameliorate the undesirable effects of chemotherapy, and consequently the post-chemotherapy cognitive disorders that ensue.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women aged 18 and over * Having completed chemotherapy (intravenous) for breast cancer (any stage) less than 12 months prior to inclusion * Having a perceived cognitive complaint that appeared during or after (\< 3 months) chemotherapy treatments (no restriction on the care protocol used) and confirmed by a FACT-Cog score compatible with a subjective cognitive disorder (score \< 117 for patients aged 18 to 49; score \< 113 for patients aged 50 to 69; score \<105 for patients aged 70 and over) * Patient eligible for photobiomodulation sessions * Patient with sufficient command of the French language to complete the study questionnaries * Patient having given written consent to participate in the trial * Socially insured patient * Patient willing to comply with all study procedures and duration Exclusion Criteria: * Known cognitive disorders prior to chemotherapy treatment * Patients with psychiatric or psychobehavioral disorders incompatible with photobiomodulation sessions * Patients who, in the 12 months prior to inclusion or at the time of inclusion, have already received photobiomodulation treatment involving "whole body" therapy (photobiomodulation in a phototherapy booth). * Patient having previously received photobiomodulation with cortical stimulation (panel or helmet) with no time limit. * Patient taking or having received capecitabine * Patients taking part in a protocol involving a drug likely to affect cognitive performance (on the investigator's advice). * Patients suffering from claustrophobia * Patient unable to read and/or unable to complete a questionnaire, in the opinion of the investigator

Primary outcome measure(s)

  • To compare, among women aged 18 and over who had undergone chemotherapy for breast cancer and had subjective cognitive impairment post-chemotherapy, the rate of those showing improvement in cognitive impairment with or without photobiomodulation (cortica — From enrollment to the end of follow-up visit at 13 weeks (V13 = V12 + 7d +/- 3d)
    Patients with an evolution subjective cognitive performance between the FACT-Cog performed at inclusion and that at the end of follow-up (S13)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier de Valenciennes Valenciennes France Recruiting

More Centre Hospitalier de Valenciennes trials in France

Study of the Prevalence of Midline Replacements and the Reasons for These Replacements Recruiting
Pilot Study on the Use of Video Laryngoscopy in Pre-hospital Settings Recruiting
Psychological Factors Influencing Cancer Post-traumatic Growth Recruiting
Multicentre Real-life Data Collection Study With CareMin650™ in the Prevention and Treatment of Oral Mucositis and Radio- and/or Chemo-induced Dermatitis Active, not recruiting
From Administration of Oral Medicines by Nurses to Controlled Self-administration: Impact on Safety of Administration During Hospitalisation Recruiting

Other trials for the same condition

Long-term Follow-up and Quality of Life of Patients Treated With Anticancer Drugs Recruiting
Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management Recruiting
Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in Paediatric Oncology Recruiting
Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments Recruiting
PACOME (PAtient Cancer Oral MEdication) Cohort of Patients Treated With Oral Anticancer Drugs Benefiting From Oncoral Multidisciplinary Monitoring in Real Life: Predictive Factors and Safety of Treatments Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06995443 on ClinicalTrials.gov ↗ ← All trials in France